# Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients

> **NCT00886366** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 26 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** AZD6714
- **DRUG:** Placebo
- **DRUG:** AZD6714
- **DRUG:** AZD6714

## Key facts

- **NCT ID:** NCT00886366
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 26 (ESTIMATED)
- **Why stopped:** Part A reached a predefined stopping criteria. Relevant doses for part B could not be established based on A and subsequently study was stopped.
- **Last updated:** 2010-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886366, "Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00886366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*